Human Igg1 Kappa Monoclonal Antibody Against Tigit

4 trials

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

0 Recruiting

4 Completed trials

2 Sponsors

21 Countries

Phase III

Phase II

Phase I/II

Phase III: 1 Phase II: 2 Phase I/II: 1

Indications tested

Squamous cell carcinoma of head and neck 1

Sponsors using this IMP

Glaxosmithkline Research & Development Limited 3 iTeos Belgium 1

All trials

4 total

A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended

2023-504753-12-00 Phase III 20 countries Glaxosmithkline Research & Development Limited
Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic … Ended

2023-503428-24-00 Phase II 12 countries Glaxosmithkline Research & Development Limited
PH2a, Platform Study of Novel Immunotherapy Combinations in Participants with Previously Untreated, Advanced/Metastatic NSCLC Ended

2023-505057-40-00 Phase II 11 countries Glaxosmithkline Research & Development Limited
A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participan… Ended

2024-512227-36-00 Phase I/II 4 countries iTeos Belgium

Showing 1–4 of 4 trials

← All drugs A–Z